142 related articles for article (PubMed ID: 29890033)
1. Bonus Effects of Antidiabetic Drugs: Possible Beneficial Effects on Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis.
Pereira CA; Carneiro FS; Matsumoto T; Tostes RC
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):523-538. PubMed ID: 29890033
[TBL] [Abstract][Full Text] [Related]
2. Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients.
Yaribeygi H; Butler AE; Barreto GE; Sahebkar A
J Cell Physiol; 2019 Mar; 234(3):2436-2446. PubMed ID: 30191997
[TBL] [Abstract][Full Text] [Related]
3. Antidiabetic agents and endothelial dysfunction - beyond glucose control.
Eriksson L; Nyström T
Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):15-25. PubMed ID: 25827165
[TBL] [Abstract][Full Text] [Related]
4. The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats.
Vallejo S; Palacios E; Romacho T; Villalobos L; Peiró C; Sánchez-Ferrer CF
Cardiovasc Diabetol; 2014 Dec; 13():158. PubMed ID: 25518980
[TBL] [Abstract][Full Text] [Related]
5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
6. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
[TBL] [Abstract][Full Text] [Related]
7. Metformin: effects on micro and macrovascular complications in type 2 diabetes.
Bailey CJ
Cardiovasc Drugs Ther; 2008 Jun; 22(3):215-24. PubMed ID: 18288595
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
Panicker GK; Karnad DR; Salvi V; Kothari S
J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
[TBL] [Abstract][Full Text] [Related]
9. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.
Isoda K; Young JL; Zirlik A; MacFarlane LA; Tsuboi N; Gerdes N; Schönbeck U; Libby P
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):611-7. PubMed ID: 16385087
[TBL] [Abstract][Full Text] [Related]
10. Oral antidiabetic agents as cardiovascular drugs.
Macfarlane DP; Paterson KR; Fisher M
Diabetes Obes Metab; 2007 Jan; 9(1):23-30. PubMed ID: 17199715
[TBL] [Abstract][Full Text] [Related]
11. Why does quick-release bromocriptine decrease cardiac events?
Bell DS
Diabetes Obes Metab; 2011 Oct; 13(10):880-4. PubMed ID: 21569186
[TBL] [Abstract][Full Text] [Related]
12. [Rheumatoid arthritis, inflammation, and atherosclerosis].
Hürlimann D; Enseleit F; Ruschitzka F
Herz; 2004 Dec; 29(8):760-8. PubMed ID: 15599672
[TBL] [Abstract][Full Text] [Related]
13. Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options.
Potenza MA; Nacci C; De Salvia MA; Sgarra L; Collino M; Montagnani M
Pharmacol Res; 2017 Jun; 120():226-241. PubMed ID: 28408314
[TBL] [Abstract][Full Text] [Related]
14. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications.
Domingueti CP; Dusse LM; Carvalho Md; de Sousa LP; Gomes KB; Fernandes AP
J Diabetes Complications; 2016; 30(4):738-45. PubMed ID: 26781070
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk factors in type 2 diabetes: the role of hyperglycaemia.
Massi-Benedetti M; Federici MO
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S120-3. PubMed ID: 10522835
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
Fisher M
Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
[TBL] [Abstract][Full Text] [Related]
17. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
[TBL] [Abstract][Full Text] [Related]
18. The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease.
Jakus V
Bratisl Lek Listy; 2000; 101(10):541-51. PubMed ID: 11218944
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
20. Endothelial dysfunction and chronic kidney disease: treatment options.
Wu-Wong JR
Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
